News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sangui Biotech: Start Of Preclinical Trials



8/6/2014 10:35:59 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WITTEN, Germany--(BUSINESS WIRE)--Together with Excellence Cluster Cardio-Pulmonary System (ECCPS) and TransMIT Gesellschaft für Technologietransfer mbH (TransMIT), Sangui is investigating new therapeutic approaches to treating septic shock and acute respiratory distress syndrome (ARDS).

Owing to their incidence rate, complexity and poor prognosis, the two diseases constitute a huge challenge in both in terms of their socio-economic impact and the associated intensive medical care, and incur unacceptably high mortality rates, despite progress made in intensive medicine. In Germany alone, 150,000 people a year are afflicted by sepsis, and the mortality rate is 30–50% even with maximum therapy. Targeted antibiotic therapy, artificial respiration, preserving the functions of organs, and supporting circulation through liquid infusions and hypertension-inducing drugs form part of an optimised therapy. The infusions of vasoconstrictive substances, such as adrenaline or noradrenaline, are intended to normalise dangerously low blood pressure. Raising the global blood pressure (macrocirculation) is, however, detrimental to the closing of small vessels (microcirculation) whose main task is peripheral oxygen delivery. This lack of oxygen poses a huge problem for many organs, such as the kidneys or intestines.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES